2019年4月19日 · GOG-252 is an open-label, randomized phase III clinical trial to determine whether IP chemotherapy would improve progression-free survival (PFS) compared with the reference IV arm paclitaxel 80 mg/m 2 once per week with IV …

2022年8月1日 · Objectives: The primary objective of this analysis of GOG 252 is to assess the overall survival of the subgroup of participants with metastatic epithelial ovarian cancer, with no more than microscopic residual disease, following their primary cytoreductive surgery followed by three chemotherapy regimens and bevacizumab. The results of the ...

2019年6月1日 · Purpose: To evaluate the impact of two different intraperitoneal (IP) chemotherapy regimens on progression-free survival (PFS) among women with newly diagnosed advanced ovarian carcinoma.

2023年4月21日 · Several study groups initiated new clinical studies to reassess intraperitoneal chemotherapy in ovarian cancer using improved randomized controlled trial designs, and three large randomized...

2022年8月1日 · Objectives: The primary objective of this analysis of GOG 252 is to assess the overall survival of the subgroup of participants with metastatic epithelial ovarian cancer, with no more than microscopic residual disease, following their primary cytoreductive surgery followed by three chemotherapy regimens and bevacizumab. The results of the ...

2016年5月19日 · The surprising results of GOG 262 raise concern that the addition of bevacizumab to all patients on GOG 252 may have obscured the effects of the individual chemotherapy regimens alone. Insufficient data exist at this time to recommend bevacizumab in combination with intraperitoneal/intravenous chemotherapy as a standard-of-care option.

2016年2月25日 · After the closure of a competing trial, Gynecologic Oncology Group (GOG)–0252 (ClinicalTrials.gov number, NCT00951496), patients with stage II or stage III disease with no residual lesions that...

2006年1月5日 · Standard chemotherapy for newly diagnosed ovarian cancer is a platinum–taxane combination. The Gynecologic Oncology Group conducted a randomized, phase 3 trial that compared intravenous paclitaxel...

Objectives: The primary objective of this analysis of GOG 252 is to assess the overall survival of the subgroup of participants with metastatic epithelial ovarian cancer, with no more than microscopic residual disease, following their primary cytoreductive surgery followed by three chemotherapy regimens and bevacizumab.

2023年11月1日 · 妇科肿瘤学组（gog）的一项试验比较了3个和6个周期的紫杉醇-卡铂辅助治疗，发现治疗时间较长的患者复发风险显著较低，但发生额外的毒性。 与非浆液性肿瘤相比，似乎只有浆液性癌从更长的辅助治疗中获益。